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Abstract
Background: Fluoroquinolones (FQ) are increasingly prescribed for children, despite being labeled for only a
limited number of labeled pediatric indications. In this multicenter retrospective drug utilization study, we analyzed
indications for systemic FQ prescriptions in hospitalized children and the appropriateness of the prescribed dose.
Methods: Using data obtained from electronic medical files, the study included all children who received a
systemic FQ prescription in two Belgian university children’s hospitals between 2010 and 2013. Two authors
reviewed prescribed daily doses. Univariate and multivariate logistic regression models were used to analyze risk
factors for inadequately dosing.
Results262 FQ prescriptions for individual patients were included for analysis. 16.8% of these prescriptions were for
labeled indications, and 35.1% were guided by bacteriological findings. Prescribed daily dose was considered to be
inappropriate in 79 prescriptions (30.2%). Other FQ than ciprofloxacin accounted for 9 prescriptions (3.4%), of which 8
were correctly dosed. Underdosing represented 45 (56.9%) dosing errors. Infants and preschool children were at
particular risk for dosing errors, with associated adjusted OR of 0.263 (0.097–0.701) and 0.254 (0.106–0.588) respectively.
Conclusions: FQ were often prescribed off-label and not guided by bacteriological findings in our study population.
Dosing errors were common, particularly in infants and preschool children. FQ prescriptions for children should be
improved by specific pediatric antimicrobial stewardship teams. Furthermore, pharmacokinetic studies should optimise
dosing recommendations for children.
Keywords: Fluoroquinolones, Children, Drug utilization study, Off-label prescribing, Prescription errors,
Antimicrobial stewardship
Background
The cornerstone of an adequate antimicrobial prescrip-
tion is the selection of the right drug for the targeted
disease, in a correct dose, and administered via an ap-
propriate route of delivery. Prescribing fluoroquinolones
(FQ) for children is controversial as labeled pediatric in-
dications for FQ prescription are limited. Moreover, the
safety of systemic FQ for growing children has been
debated for a long time [1, 2]. Ciprofloxacin, the proto-
type FQ, is labeled in the United States (US) for treating
complicated urinary tract infections (UTI), and treat-
ment and prevention of inhalation anthrax in children
[3]. In Europe, ciprofloxacin is labeled for the above-
mentioned indications, and additionally for treatment of
Pseudomonas aeruginosa infections in cystic fibrosis
(CF) patients [4]. Furthermore, both labeling guidelines
state that beyond these indications, FQ should be
reserve antibiotics for children in case of difficult to treat
infections in absence of other available agents [3, 4].
Nevertheless, 520,000 children were prescribed a FQ in
the USA in 2002 [5], the most recent year for which data
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could be found. Prescribing FQ for children has some
advantages, even in the absence of indications outlined
in labeling guidelines. First, FQ cover a broad spectrum
of bacteriae [6]. Second, pharmacokinetic (PK) charac-
teristics of systemic FQ are favorable. The bioavailability
of common FQ agents is usually high and FQ typically
penetrate in deep compartments [7–9]. These PK proper-
ties can be of particular interest in pediatric pharmaco-
therapy, as intravenous access is challenging in children,
creating a higher need for oral alternatives. Further, micro-
bial cultures are usually not easy to obtain in children,
resulting in empiric treatments. However, the safety of FQ
for growing children has been debated, as experiments in
different juvenile animals showed irreversible cartilage
tissue damage after exposure to systemic FQ [10–12].
These findings likely influence both the labeling guidelines
and prescribers behavior, although there is no evidence of
significant irreversible musculoskeletal side effects result-
ing from FQ use in children [13, 14]. Another concern in
liberally prescribing FQ for children is the rapidly growing
resistance rates of different germs for FQ [15, 16]. In this
retrospective multicenter drug utilization study, we aimed
to investigate indications for FQ prescription in a popula-
tion of children hospitalized in two Belgian university chil-
dren’s hospitals. Additionally, another goal was to assess
the adequacy of prescribed doses, and risk factors for
incorrectly dosed FQ prescriptions within this population.
Methods
Setting
The Department of Pediatrics at Ghent University
Hospital is a tertiary referral hospital for the Western
region of Belgium that admits around 4000 children each
year. Universitair Ziekenhuis Brussel is the hospital of the
Dutch-speaking university of Brussels (Vrije Universiteit
Brussel), and serves as a tertiary referral hospital for the
Brussels region. Its pediatric department admits about
2500 children annually. Both university children’s hospi-
tals include all different subspecialities. During the study
period, no hospital formulary of FQ dosing for either nor-
mal weight or obese children was available in the study
centers. Children were dosed on total body weight. Fur-
thermore. not all antibiotic prescriptions were reviewed by
an antimicrobial stewardship (AMS) program. However,
treating physicians usually used either the Dutch Paediatric
Formulary, or labeling guidelines for dosing recommenda-
tions. Current pediatric dosing recommendations of FQ in
the study centers are shown in Table 1.
Participants
The pharmacy information system retrieved all FQ pre-
scriptions for hospitalized children between 2010 and 2013
at both study centers. Information about the patients, indi-
cations and other details of their FQ prescription, and
results of microbial cultures were obtained from the elec-
tronic medical files. For patients who were hospitalized re-
peatedly during the study period, only the first prescription
per indication was included.
Data classification
Participants older than 2 years of age were classified as
being overweight or obese, if their body mass index
(BMI) exceeded respectively the p85 or p95 of their sex
and age specific reference value of Belgian children
(Vrije Universiteit Brussel, 2004). If no length was avail-
able, participants were classified as overweight or obese
if their weight exceeded the 85th centile for their age
and sex specific curve. All prescriptions were classified
as being either on-label or off-label according to the
guidelines of the European Medicines Agency (EMA)
[4]. More precisely, on-label indications are respiratory
infections in CF patients, complicated UTI and pyelo-
nephritis, and treatment and prophylaxis of inhalation
anthrax. The first and second author independently
assessed the prescribed daily doses per patient. Recom-
mended doses of FQ in our centers are summarized in
Table 1, and were obtained from available studies in ei-
ther labeling leaflets or the Dutch Paediatric Formulary.
Underdosing was defined, in absence of formal defini-
tions, as a dose per kilogram of at least 5% below the
minimum recommended dose per kilogram, while not
exceeding the maximum dose. Similarly, overdosing was
defined of a dose per kilogram that exceeds at least 5%
of the maximum recommended dose per kilogram. Dis-
crepancies between the two reviewers were resolved by
the last author.
Data analysis
Continuous data are presented as median with inter-
quartile range, if not normally distributed, or as mean
with 95% confidence interval if normally distributed.
Categorical data are expressed as either frequencies,
fractions, or percentages, unless stated otherwise. Chi-
square tests were used to test differences in proportions
of categorical variables between subgroups. Univariate
logistic regression models were used for analyzing risk
factors for inadequate prescriptions. A multivariate lo-
gistic regression model was used to assess interaction
between different predictors. Appropriateness of pre-
scribed dose, classified as described previously, was used
as outcome variable in all regression analyses. Age was
stratified according to different development stages: in-
fants (< 1 year), toddlers (12 months–36 months), pre-
school children (3–6 years), school children (6–12 years),
and young adolescents (12–18 years). Akaike Information
Criterion was used for assessing quality of the multivariate
logistic regression model. A p-level of less than 0,05 was
considered statistically significant in all analyses. Data
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were analyzed using SPSS for Windows version 23 (SPSS
Inc., Chicago, IL).
Results
A total of 262 FQ prescriptions for unique patients
were identified within the study period, of which 158
(60.3%) were at Ghent University Hospital. Table 2
displays basic characteristics of our study population.
Length was unavailable for 21 participants older than
2 years of age, so that they were classified as being
overweight or obese based on their age and sex
specific weight curve.
Most children (57.6%) had significant chronic comor-
bidity such as any type of cancer (20.2%), a neurologic
disease (14.5%), or congenital anomalies of the kidneys
and urinary tract (CAKUT; 6.9%). Table 2 summarizes
details about the FQ prescriptions. Ciprofloxacin was by
far the most frequently prescribed FQ, representing 253
prescriptions (96.6%). Other prescribed FQ were moxi-
floxacin (1.1%), norfloxacin (0.4%), and levofloxacin
(1.9%). Main indications for FQ prescription were
treatment of central nervous system (CNS) infections
(65 prescriptions, 24.8%), prophylaxis of febrile neutro-
penia (49 prescriptions, 18.7%), respiratory tract infec-
tions and pneumonias (48 prescriptions, 18.3%), and
UTI (31 prescriptions, 11.8%) (Table 3). Overall, the
number of on-label FQ prescriptions was 43 (16.4%).
Prescription was guided by a microbial culture in 62
cases (35.1%), indicating empiric treatments in the
majority of our study population. 79 prescriptions
(30.2%), of which 78 were ciprofloxacin prescriptions,
were considered to be inaccurately dosed. Underdosing
was the most common type, as 57.1% of all inaccurately
dosed prescriptions were underdosed. The percentage of
underdosing was similar in our population of overweight
and obese children compared to normal weight children
(17.9% vs. 17.4%, p = 0.956).
Table 4 displays the results of logistic regression ana-
lyses, aimed at identifying risk factors for dosing errors.
In the univariate logistic regression analysis, children
younger than 6 years of age were at particular risk of
receiving an inadequately dosed prescription. Children
who were prescribed an FQ other than ciprofloxacin,
Table 2 characteristics of the study population
Age 5.23 (1.75–12.44) median, interquartile range
< 1 years: 26 (9.9%)
1–3 years: 65 (24.8%)
3–6 years: 43 (16.4%)
6–12 years: 54 (20.6%)
12–18 years: 74 (28.2%)
Weight 18,6 kg (11.3–38.7) median, interquartile range
BMIa 16.44 (15.00–18.76) median, interquartile range
Fraction overweight
or obesea




Study center Ghent University Hospital: 158 (60.3%)
Universitair Ziekenhuis Brussel: 104 (39.7%)
Sex Male 144 (55%), female 118 (45%)
Comorbidity Malignancies: 53 (20.2%) of which hematologic:
39 (73.6%)
Cystic fibrosis: 14 (5.3%)
Benign blood disorders and immune
deficiencies: 14 (5.3%)
Neurologic disorder: 38 (14.5%)
Congenital Anomalies of the Kidneys and
Urinary Tract: 18 (6.9%)
Inflammatory bowel disease: 7 (2.7%)
Heart defect: 3 (1.1%)
Transplant organ: 3 (1.1%)
Congenital hernia diaphragmatica: 1 (0.4%)
None: 111 (42.4%)
Department Academic pediatrics ward: 104 (39.7%)
Pediatric oncology: 53 (20.2%)
PICU: 105 (40.1%)
aDefined as BMI exceeding respectively p85 or p95 for age and sex specific
curves for Belgian children.
#Starting for children of 2 years and older
Table 1 recommended doses of systemic FQ in the study centers
FQ Adequate oral dose Adequate intravenous dose
Ciprofloxacin non-CF: 20–30 mg/kg/day in 2 doses, max. 500 mg/dose.
CF: 40 mg/kg/day in 2 doses, max. 750 mg/dose
non-CF: 20–30 mg/kg/day in 2–3 doses, max. 400 mg/dose.
CF: 30–40 mg/kg/day in 2–3 doses, max. 1200 mg/day.
Moxifloxacin 10 mg/kg/day in one dose, max. 400 mg/dose.
Levofloxacin < 5 years: 20 mg/kg/day in 2 doses, max. 1000 mg/day.
> 5 years: 10 mg/kg/day in 1 dose, max. 1000 mg/day.
Norfloxacin Therapeutic indications: 10 mg/kg/day in one dose, max. 400 mg/dose.
Prophylactic indications: 2–5 mg/kg/day in 2 doses, max. 400 mg/dose.
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had a statistically non-significant odds ratio (OR) of 3.56
for receiving an adequately dosed prescription. Children
treated both intravenously and for an off-label indica-
tion, were at risk for an inadequately dosed prescription.
However, these associated OR were not statistically
significant. Other potential risk factors were also not
statistically significant in the univariate analyses. In the
final multivariate logistic regression model, when con-
trolled for the sort of FQ prescribed, OR for infants and
preschool children remained statistically significant.
Table 4: unadjusted and adjusted odds ratios of different
predictors of inadequately dosed prescriptions. Displayed
are odds ratios with their 95% confidence intervals and
corresponding p-values. For age categories, the stratum
12–18 years is the reference stratum as inadequately
dosed prescriptions are least frequent in this stratum.
Discussion
In this multicenter retrospective drug utilization study, we
analyzed prescriptions of systemic FQ for hospitalized
children in two Belgian university children’s hospitals, cov-
ering a three-year period. Ciprofloxacin was by far the
most frequently prescribed FQ in our study population,
representing 96.6% of all prescriptions. FQ prescriptions
in our population were off-label in 83.6%, and not guided
by a microbial culture in 64.9% of cases. Off-label medica-
tion use is very common in children, as is widely argued
by professional societies [17]. However, at least some evi-
dence is available for the major groups of off-label indica-
tions in our study population.
CNS infections represent the largest group of off-label
indications for FQ prescription in our study population.
This group consists of children admitted to the PICU
with suspicion of meningoencephalitis. Beta lactams,
particularly cephalosporins, are used in many centers for
empiric treatment of meningoencephalitis. Cephalospo-
rins penetrate into cerebrospinal fluid (CSF) of inflamed
meninges, and usually cover Streptococcus pneumoniae,
Neiseria meningitidis, and Haemophilus influenzae,
which are common bacteria that cause meningitis.
Additionally, Mycoplasma pneumoniae accounts for
10–30% of all pathogens causing encephalitis [18]. All
antibiotics that target the cell wall, such as beta
lactams and glycopeptides, are ineffective for Myco-
plasma pneumoniae as this germ lacks a cell wall.
Diagnosis of Mycoplasma pneumonia is challenging,
given the complexity of culturing Mycoplasma strains
[19], resulting in detection rates of Mycoplasma anti-
gens in CSF as low as 0–14% [20]. Macrolides,
tetracyclines, and FQ are usually effective against
Mycoplasma pneumoniae. Yet, neither macrolides nor
tetracyclines penetrate into CSF. Furthermore, macro-
lide resistance of Mycoplasma pneumoniae is growing
worldwide, while FQ resistance has not yet been
Table 3 characteristics of the prescriptions





Respiratory infections in CF patients: 13 (5.0%)
Complicated UTI and pyelonephritis: 31 (11.8%)
Off-label
Prophylaxis of febrile neutropenia: 49 (18.7%)
Pneumonia: 34 (13.0%)
Multidrug-resistant tuberculosis: 1 (0.4%)
Sepsis: 6 (2.3%)
Ocular trauma: 1 (0.4%)
Intraabdominal abcess and peritonitis: 15 (5.7%)
Enteritis: 13 (5.0%)
Meningitis and/or encephalitis: 65 (24.8%)
Epididymitis: 2 (0.8%)
Skin and soft tissue infections: 27 (10.3%),
including burns and surgical site infections
Osteomyelitis: 2 (0.8%)
Q-fever: 1 (0.4%)
Microbial cultures None: 170 (64.9%)
Pseudomonas aeruginosa: 51 (19.5%)
Colonic bacteriae: 17 (6.5%)
(Escherichia coli, Enterobacter cloaca,
Citrobacter freundi)
Stenotrophomonas maltophilia: 7 (2.7%)
Salmonalla species (blood culture): 3 (1.1%)
Klebsiella pneumoniae: 4 (1.5%)
Mycoplasma pneumoniae: 2 (0.8%)
Mycobacterium tuberculosis: 1 (0.4%)
Acinetobacter species: 1 (0.4%)
Proteus mirabilis: 1 (0.4%)
Neiseria meningitidis, serogroup B: 1 (0.4%)
Morganella morgani: 1 (0.4%)
Route of administration Orally: 130 (49.6%)
IV: 132 (50.4%)
Doses per day 1: 5 (1.9%)
2: 240 (91.6%)
3: 17 (6.5%)




Unnecessarily thrice daily dosing PO: 9 (11,4%)
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reported [21]. Therefore, FQ are preferred in our cen-
ters, as they usually reach therapeutic concentrations
in cerebrospinal fluid [7–9].
Prophylaxis of febrile episodes in neutropenic patients,
usually under treatment for childhood cancer, was the
second most frequent off-label indication for FQ pre-
scription in our study population. Progress in medical
research has significantly improved long-term prognosis
of most types of childhood cancer. However, infections
remain a leading cause of morbidity and mortality in
these patients. A meta-analysis of randomized placebo-
controlled trials, in adult neutropenic patients under
treatment for solid tumors showed that FQ prophylaxis
reduced febrile episodes and overall mortality [22]. Fur-
thermore, a Cochrane review pooled data of seven trials
involving 850 adult neutropenic patients, and found that
prophylaxis with FQ when compared to trimethoprim-
sulfamethoxazole resulted in equal outcomes, but fewer
side effects and less resistance to the drugs after
treatment [23]. This has made FQ prophylaxis part of
the ‘standard of care’ for adult neutropenic patients in
many centers worldwide. Fewer studies are available on
prophylactic antibiotics for febrile neutropenia in children.
Previous studies of trimethoprim-sulfamethoxazole, erythro-
mycin, and amoxicillin-clavulanic acid did not show signifi-
cantly improved patient outcomes [24, 25]. To our
knowledge only one RCT has investigated the value of FQ
prophylaxis in neutropenic children [26]. In this Thai
placebo controlled RCT, ciprofloxacin showed a statistically
significant risk reduction of 23.0% (− 45.0% to − 0.9%) in
febrile episodes in neutropenic children under treatment for
acute leukemia. Still, no significant risk reduction for febrile
episodes was observed, either in neutropenic children with
lymphomas or in the consolidation phase of chemotherapy.
No significant short-term adverse effects were observed, nei-
ther in the intervention group nor in the control group [26].
A retrospective study analyzed 153 chemotherapy courses in
45 neutropenic children under treatment for acute myeloid
leukemia [27]. Sixty-four chemotherapy courses were under
ciprofloxacin prophylaxis. This prophylaxis did not change
the incidence of febrile or infectious episodes, or number of
days of fever. Yet, ciprofloxacin prophylaxis was associated
with a significant decrease in infections caused by Gram-
negative germs and a concomitant significant increase in
bacteremia’s caused by Viridans streptococci [27]. A concern
about long-term consequences of prolonged FQ prophylaxis
is increasing antimicrobial resistance, due to a selective pres-
sure on intestinal flora. FQ resistance correlates with effect-
ive serum concentrations of FQ, at least in mycobacteriae
[28]. For this reason, specific PK studies in children with
cancer would be highly useful, as PK characteristics can be
significantly influenced by age, maturational, and disease
characteristics in children under treatment for cancer.
In our study population, 18 out of 34 non-CF patients
for whom FQ were administered for pneumonias, had
neurologic comorbidity such as cerebral palsies and
muscular diseases. These patients, who often reside in
specialized (para)medic institutions, suffer from complex
pneumonias caused by health care associated pathogens,
such as Pseudomonas and Klebsiella strains, which may
justify FQ prescription. Ten of 34 patients with pneumo-
nia had no significant medical history. Reasons for FQ
administration to them were possibly empiric treatment
of both typical and atypical germs. As mentioned before,
Table 4 risk factors for receiving an inadequately dosed FQ prescription
Unadjusted Odds Ratio Adjusted Odds Ratio
Age
< 1 years 0.249 (0.092–0.658) p = 0.005 0.263 (0.097–0.701) p = 0.008
1–3 years 0.447 (0.198–0.976) p = 0.046 0.467 (0.206–1.027) p = 0.062
3–6 years 0.269 (0.113–0.622) p = 0.002 0.254 (0.106–0.588) p = 0.020
6–12 years 0.672 (0.281–1.605) p = 0.368 0.702 (0.292–1.684) p = 0.425
12–18 years - (reference category) - (reference category)
CF vs. non-CF 1.332 (0.398–3.992) p = 0.618 –
IV vs. orally 0.816 (0.480–1.384) p = 0.451 –
Study center 1.294 (0.753–2.253) p = 0.356 –
Off-label vs. on-label indication 0.780 (0.357–1.597) p = 0.512 –
Culture absent vs. present 1.292 (0.744–2.226) p = 0.358 –
Other FQ vs. ciprofloxacin 3.566 (0.638–66.71) p = 0.234 2.601 (0.436–49.86) p = 0.382
Department
Academic pediatrics ward 1.238 (0.686–2.248) p = 0.479
Oncology 1.213 (0.595–2.549) p = 0.601
PICU - (reference category)
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macrolides, and tetracyclines are usually preferred when
treating atypical germs, but may be unwanted because of
rising antimicrobial resistance rates and adverse effects.
Moxifloxacin was administered for one participant for
treating multidrug-resistant tuberculosis (MDR-TB). In
adults, FQ are widely used in treatment of MDR-TB
[29]. FQ achieve antimicrobial activity by interfering
with mycobacterial gyrase enzymes [28]. No prospective
RCT has, to our knowledge, proven efficacy of FQ treat-
ment for MDR-TB in children. Though, resistance
patterns of mycobacteriae emerge rapidly, probably due
to mutations in gyr A genes. The rate of mutations de-
pends on effective FQ concentrations. There is a paucity
on specific PK studies in MDR-TB infected children, es-
pecially those younger than 5 years of age, and HIV
infected children. Yet, a South African study showed
substantially lower serum concentrations of moxifloxa-
cin after oral administration, when compared to adults
[28], probably due to faster elimination in children.
Treatment of skin- and soft tissue infections account
for 10.3% of our analyzed prescriptions. Usually, germs
as Staphylococcus aureus and Streptococcus pyogenes are
responsible for these infections, and topical antibiotics
are preferred for less complicated infections. If systemic
antibiotics are indicated, then flucloxacillin, amoxicillin-
clavulanic acid, trimethoprim-sulfamethoxazole, and
clindamycin are first line therapies for these infections
[25]. Linezolid and vancomycin should be reserved for
more severe or hospital acquired infections [25]. Yet,
skin and soft tissue infections in our study population
were often very complicated, as for example infected
burns caused by Pseudomonas strains. In a skin microdi-
alysis study in healthy male volunteers, systemic cipro-
floxacin reached sufficient antimicrobial activity against
Pseudomonas aeruginosa in the skin [30, 31]. No study
has, to our knowledge, investigated skin penetration of
FQ in children with complicated skin infections.
Bioavailability of most FQ is high after oral administra-
tion. Nevertheless, approximately half of our study
population (50.4%) received their FQ intravenously. As
the majority of our study population were hospitalized
in advanced care departments, being either the PICU or
the pediatric oncology unit, it is likely that clinical con-
ditions such as vomiting, mucositis and oral ulcers, or
significant respiratory distress, required intravenous
treatment, because oral ingestion was not reliable. Yet,
alternative antibiotics should be considered on a case by
case basis if the intravenous route is used, for reasons of
antimicrobial resistance and financial considerations.
Approximately a third (30.2%) of FQ prescriptions in
our study population were considered inadequately
dosed. Different information systems such as the Dutch
Paediatric Formulary [32] and the Stanford Guide to
Antimicrobial Therapy were available in the centers
during the study period, but no pediatric hospital formu-
lary for FQ was available. All except one inadequately
dosed prescriptions were ciprofloxacin prescriptions. In
both univariate and multivariate logistic regression
models, prescription of a non-ciprofloxacin FQ was as-
sociated with an OR of about 3 in favor of receiving an
adequately prescribed dose. One explanation for this
might be that due to the small amount of levofloxacin,
moxifloxacin, and norfloxacin prescriptions in our popu-
lation, prescribers might have been more cautious in
prescribing these non-ciprofloxacin FQ, resulting in a
higher likelihood of prescribing a correct dose. However,
the corresponding 95% confidence interval is very wide
and therefore statistically insignificant, most likely due
to the relatively low number of non-ciprofloxacin pre-
scriptions. In our multivariate logistic regression model,
age was statistically the most significant risk factor for
receiving an inadequately dosed FQ prescription. Dosing
errors were least frequent in adolescents, most likely due
to similarities with widely available adult dosing recom-
mendations. Infants and preschool children were at par-
ticular risk for dosing errors, with adjusted OR of 0.263
and 0.254 respectively. In both study centers, ciprofloxa-
cin is available both in a liquid formulation, and in tab-
lets of 250 mg and 500 mg. The liquid formulation was
prescribed for all infants, whereas a combination of split
tablets and liquid formulation was prescribed for pre-
school children. A rounding-off effect possibly explains a
proportion of inadequately prescribed doses for children
in these age categories.
Underdosing was the most common type of dosing
error, and is undesirable as subtherapeutic serum con-
centrations of FQ result in rapidly emerging resistance
rates, at least in mycobacteria [28] and Pseudomonas
aeruginosa [33]. There is no universal definition of
underdosing. Yet, in absence of high level pharmacoki-
netic studies in children, the prescribed dose per kilo-
gram of FQ should at least be within the recommended
range if the maximum recommended dose has not been
reached. Different studies show that even advised doses
per kilogram of different antibiotics in children are ex-
creted faster than in adults, as has been shown for moxi-
floxacin [28] and for amoxicillin-clavulanic acid [34].
Therefore, we chose a sharp criterion for underdosing,
i.e. a dose per kilogram of less than 95% of the minimum
advised dose.
Overweight and obesity are increasingly prevalent
among children, which creates specific dilemmas in drug
dosing [35]. There were no specific recommendations
available for FQ dosing for overweight and obese chil-
dren in our centers, during the study period. Further-
more, there is no consensus on which body size
descriptor should be used for dosing FQ in obese
children. Some authors advocate dosing on total body
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weight, while others recommend dosing on metric that
adjusts for body composition, such as adjusted body
weight [36]. In our population, underdosing was similar
between overweight and obese children, and normal
weight children. Accordingly, overweight and obesity are
unlikely to have influenced the proportion of underdos-
ing in our study population.
Compared to a retrospective [37] and a prospective
[38] study in Parisian children’s hospitals, our study
showed a similar amount of off-label FQ prescriptions.
Furthermore, frequent off-label indications for FQ pre-
scription in these studies were prophylaxis of febrile
neutropenia, intra-abdominal infections and pneumonia,
all similar to our study population. The amount of cor-
rectly dosed prescriptions in our study was 69.8%, which
is substantially lower than in these Parisian studies:
84.7% and 88% respectively [37, 38]. Not all antibiotic
prescriptions were routinely reviewed by a formal AMS
program. This does by no means justify dosing errors, as
dosing is a joint responsibility of the prescriber and the
hospital pharmacy. However, specific for antibiotics,
drug dosing is important in achieving therapeutic suc-
cess, and dosing can differ both on patient and disease
characteristics, particularly in children. Feedback on the
correct drug for a given indication, the dose, route of de-
livery, and treatment duration are key tasks of pediatric
AMS programs [39]. Furthermore, a recent study in
Germany showed an increase in dosage accuracy (78.8 vs.
97.6%) of different antibiotics after implementation of a
pediatric AMS program [40]. Besides dose optimization,
pediatric AMS programs in our hospitals could have
reduced the number of FQ administered via the IV route,
and have used other agents as much as possible.
This is, to our knowledge, the largest multicenter drug
utilization study that analyzes FQ prescriptions for hospi-
talized children. A limitation of this study is its retrospect-
ive design, which makes it impossible to reliably study
adverse effects of FQ administration. However, adverse
effects of FQ in children have been extensively studied
previously [13], and was for this reason not a part of our
study protocol. Another possible limitation of retrospect-
ive study designs is information bias. Yet, the high quality
of electronic medical files at both study sites guaranteed
complete data extraction, leaving minimal missing values
for our parameters. Further, as our study was conducted
within two university children’s hospitals with important
referral functions for complex pediatric pathologies and
for critically ill children, our results are probably selection
biased to tertiary pathologies.
Conclusions
In our study, 83.2% of systemic FQ prescriptions were
off-label prescribed for hospitalized children. Dosing
errors were present in 30.2% of all prescriptions, with
infants and preschool children at particular risk for
receiving an inadequately dosed prescription. Our study
results suggest that FQ prescriptions for hospitalized
children should be optimized. AMS programs should
control for inappropriate FQ prescriptions, and adjust
inappropriate doses. These programs should focus on
special populations at risk. Furthermore, pharmacoki-
netic studies are necessary for identifying optimal doses
for frequent off-label indications.
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